- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07636720
Sensing in Sleep Deep Brain Stimulation
Sensing in Sleep and Deep Brain Stimulation
Participants in this study have Parkinson's Disease and already have a device, called the Percept RC Deep Brain Stimulation device implanted. People with Parkinson's disease often have issues related to sleep such as bad quality of sleep, waking up often and sleep apnea (breathing stops and starts during sleep).
For this study, participants will be sleeping overnight in the study sleep lab for two nights. One night, Deep Brain Stimulation (DBS) device turned on and one night with the DBS off, either in this order or the reverse.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Eleni O Vaou, MD
- Telefonnummer: 210 450 8048
- E-mail: vaou@uthscsa.edu
Undersøgelse Kontakt Backup
- Navn: Omalys Biggs Rodriguez
- Telefonnummer: 210-450-7547
- E-mail: biggsrodrigu@uthscsa.edu
Studiesteder
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- The University of Texas Health Science Center at San Antonio - Brain Health Center
-
Kontakt:
- Omalys Biggs Rodriguez
- Telefonnummer: 210-450-8456
- E-mail: biggsrodrigu@uthscsa.edu
-
Kontakt:
- Eleni O Vaou, MD
- Telefonnummer: 210-450 8048
- E-mail: vaou@uthscsa.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Ability of subject to understand and the willingness to sign a written informed consent document.
- Males and females; Age 40-80
- Subjects with the diagnosis of idiopathic PD consistent with the United Kingdom Parkinson Disease society brain bank criteria, or documented diagnosis of Parkinson Disease who have a Deep Brain Implant, Percept RC device to subthalamic nucleus (STN) or Globus pallidus internus (GPi).
- Willingness to adhere to the PSG regimen and turn DBS off for one night.
- A score of ≥23 on the Montreal Cognitive Assessment (MoCA)
- Be willing to stop any sleep hypnotics such as benzodiazepines and Ambien, with a 3 day washout period.
Exclusion Criteria:
- History of severe cardiovascular disease, untreated obstructive sleep apnea (OSA).
- History of other neurological disorders affecting the central nervous system such as stroke, multiple sclerosis, tumors, amyotrophic lateral sclerosis or muscle disease such as muscular dystrophy, myopathy.
- History of Dementia.
- Report dopaminergic medication changes in the past month.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: STN-DBS Group
Participants diagnosed with Parkinson's Disease who have subthalamic nucleus (STN) deep brain stimulation as a primary target for their condition
|
Patients will undergo a 2-night Polysomnography (PSG).
Stimulation will be set to "ON" stimulation for the 1st PSG night, then will cross over the 2nd PSG study night in the opposite stimulation state.
Each subject will act as their own control.
Andre navne:
Patients will undergo a 2-night Polysomnography (PSG).
Stimulation will be set to "OFF" stimulation for the 1st PSG night, then will cross over the 2nd PSG study night in the opposite stimulation state.
Each subject will act as their own control.
Andre navne:
|
|
Eksperimentel: GPi-DBS Group
Participants diagnosed with Parkinson's Disease who have Globus Pallidus internus (GPi) deep brain stimulation as a primary target for their condition.
|
Patients will undergo a 2-night Polysomnography (PSG).
Stimulation will be set to "ON" stimulation for the 1st PSG night, then will cross over the 2nd PSG study night in the opposite stimulation state.
Each subject will act as their own control.
Andre navne:
Patients will undergo a 2-night Polysomnography (PSG).
Stimulation will be set to "OFF" stimulation for the 1st PSG night, then will cross over the 2nd PSG study night in the opposite stimulation state.
Each subject will act as their own control.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sensing & Sleep: Parkinson's Disease Sleep Assessment
Tidsramme: Day 1 to Day 14
|
A 7 item to rate sleep experience scored 0=unsure, 1=No and 2=Yes.
Total range of scores is from 0-14 with a higher score indicating more issues with sleep
|
Day 1 to Day 14
|
|
Motor severity
Tidsramme: Baseline to Day 14
|
Motor severity will be assessed by the Movement Disorders Society - Unified Parkinson's Disease Rating Scale - part III.
This scale is the gold standard for measuring the severity and progression of PD.
Part III entails motor examination which consists of 18 questions that are scored on a 0-4 scale.
Higher scores suggest greater severity and progressing disease.
|
Baseline to Day 14
|
|
Epworth Sleepiness Scale (ESS)
Tidsramme: Baseline to Day 14
|
The ESS is a short, self-administered survey that asks respondents to rate their likelihood of dozing off in eight different situations on a scale of 0-3.
The total score ranges from 0-24, and is used to estimate if the respondent has excessive daytime sleepiness that may require medical attention.
A score over 10 is abnormal.
Higher scores suggest greater severity of daytime sleepiness.
|
Baseline to Day 14
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Eleni O Vaou, MD, The University of Texas Health Science Center at San Antonio
- Ledende efterforsker: Pablo Coss, MD, The University of Texas Health Science Center at San Antonio
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Synukleinopatier
- Neurologiske manifestationer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Psykiske lidelser
- Neurodegenerative sygdomme
- Bevægelsesforstyrrelser
- Basal Ganglia Sygdomme
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Dyssomnier
- Parkinsons sygdom
- Søvnvågningsforstyrrelser
- Parkinsonlidelser
Andre undersøgelses-id-numre
- STUDY00000600
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Polysomnography ON stimulation then OFF
-
University of AarhusAarhus University HospitalRekruttering
-
University of BolognaAfsluttet
-
Shanghai Mental Health CenterHuashan HospitalRekruttering
-
The University of Texas Health Science Center,...AfsluttetHjertefejl | LVADForenede Stater
-
Fisher and Paykel HealthcareAfsluttetObstruktiv søvnapnøForenede Stater
-
Fundació Institut de Recerca de l'Hospital de la...Aktiv, ikke rekrutterendeDyb hjernestimulation | Behandlingsresistent skizofreniSpanien
-
Vanderbilt University Medical CenterAfsluttetSlag | Hæmolyse | TromboemboliForenede Stater
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaAfsluttetIldfast skizofreniSpanien
-
Andrew KrystalRekrutteringStørre depressiv lidelseForenede Stater
-
Midwest Heart FoundationBoston Scientific Corporation; Medtronic; Abbott Medical DevicesAfsluttetHjertefejl | Arytmi | Pludselig hjertedødForenede Stater